EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

HBV Integration in Clinical Management of Hepatocellular Carcinoma by Liquid Biopsy

Xueying Lyu, Zita Hoi-Ying Chan, Daniel Wai-Hung Ho

Oncology · 02.03.2026 · 104 (8) · 970-983

DOI: 10.1159/000551214 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology, online erschienen am 02.03.2026. Verfasst von Xueying Lyu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B virus, Virus Integration. Die Arbeit nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Hepatitis B virus (HBV) infection is a significant risk factor for hepatocellular carcinoma (HCC). During infection, HBV DNA integrates into the host genome, promoting hepatocarcinogenesis through both gene-dependent and gene-independent mechanisms. It can activate oncogenic gene transcription or produce chimeric and novel proteins that contribute to tumorigenesis. On the other hand, it also compromises genomic stability on a large scale. Furthermore, HBV integration can alter the liver microenvironment, fostering conditions conducive to tumor development. HCC remains one of the most challenging cancers to treat, primarily due to the incomplete understanding of HCC, inadequate diagnostic and prognostic strategies, and limited effective therapeutic options. Summary: Liquid biopsy represents a significant advancement in oncology, offering a noninvasive tool for cancer detection and management. HBV integration detection through liquid biopsy serves as a promising strategy for managing HBV-associated HCC. Importantly, it exhibits preferential patterns that differentiate HCC from chronic hepatitis or cirrhosis in patients, making it a potential biomarker for HCC diagnosis. Moreover, the quantification of HBV-host chimeric reads in the bloodstream can indicate the presence of residual tumor cells post-surgery, serving as a promising biomarker for the screening of HCC recurrence. HBV integration additionally contributes to the production of HBV surface antigen, which is crucial for achieving a functional cure for HBV infection and influences the efficacy of antiviral treatments. Key Messages: HBV integration plays a pivotal role in hepatocarcinogenesis, and its detection via liquid biopsy will greatly enhance the clinical management of HBV-associated HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis B virusVirus IntegrationHepatitis BHumansLiquid BiopsyBiomarkers, TumorDNA, Viral

Stichwörter der Autor:innen

HBV integrationHepatocarcinogenesisLiquid biopsy

Substanzen

Biomarkers, TumorDNA, Viral

Autor:innen und Institutionen

  • Department of Pathology and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong, China.
  • Department of Pathology and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong, China, dwhho@hku.hk.

Zitieren

APA

Lyu, X., Chan, Z. H., & Ho, D. W. (2026). HBV Integration in Clinical Management of Hepatocellular Carcinoma by Liquid Biopsy. Oncology, 104(8), 970-983. https://doi.org/10.1159/000551214

Vancouver

Lyu X, Chan ZH, Ho DW. HBV Integration in Clinical Management of Hepatocellular Carcinoma by Liquid Biopsy. Oncology. 2026;104(8):970-983. doi:10.1159/000551214

BibTeX
@article{Lyu2026,
  author = {Lyu, Xueying and Chan, Zita Hoi-Ying and Ho, Daniel Wai-Hung},
  title = {HBV Integration in Clinical Management of Hepatocellular Carcinoma by Liquid Biopsy},
  journal = {Oncology},
  year = {2026},
  volume = {104},
  number = {8},
  pages = {970--983},
  doi = {10.1159/000551214}
}
Kostenlos starten →